KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Castle Biosciences (CSTL) Accounts Payables: 2018-2024

Historic Accounts Payables for Castle Biosciences (CSTL) over the last 7 years, with Dec 2024 value amounting to $6.9 million.

  • Castle Biosciences' Accounts Payables rose 79.31% to $12.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $12.2 million, marking a year-over-year increase of 79.31%. This contributed to the annual value of $6.9 million for FY2024, which is 32.79% down from last year.
  • Per Castle Biosciences' latest filing, its Accounts Payables stood at $6.9 million for FY2024, which was down 32.79% from $10.3 million recorded in FY2023.
  • Over the past 5 years, Castle Biosciences' Accounts Payables peaked at $10.3 million during FY2023, and registered a low of $2.1 million during FY2020.
  • Its 3-year average for Accounts Payables is $7.3 million, with a median of $6.9 million in 2024.
  • Its Accounts Payables has fluctuated over the past 5 years, first surged by 117.04% in 2023, then tumbled by 32.79% in 2024.
  • Over the past 5 years, Castle Biosciences' Accounts Payables (Yearly) stood at $2.1 million in 2020, then increased by 21.35% to $2.5 million in 2021, then soared by 85.82% to $4.7 million in 2022, then skyrocketed by 117.04% to $10.3 million in 2023, then plummeted by 32.79% to $6.9 million in 2024.